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Abstract
Background: Coagulation factor VIII (FVIII) deficiency leads to haemophilia A. Conversely, elevated plasma levels are a
strong predictor of recurrent venous thromboemboli and pulmonary hypertension phenotypes in which in situ thromboses
are implicated. Extrahepatic sources of plasma FVIII are implicated, but have remained elusive.
Methodology/Principal Findings: Immunohistochemistry of normal human lung tissue, and confocal microscopy, flow
cytometry, and ELISA quantification of conditioned media from normal primary endothelial cells were used to examine
endothelial expression of FVIII and coexpression with von Willebrand Factor (vWF), which protects secreted FVIII heavy
chain from rapid proteloysis. FVIII transcripts predicted from database mining were identified by rt-PCR and sequencing.
FVIII mAb-reactive material was demonstrated in CD31+ endothelial cells in normal human lung tissue, and in primary
pulmonary artery, pulmonary microvascular, and dermal microvascular endothelial cells. In pulmonary endothelial cells, this
protein occasionally colocalized with vWF, centered on Weibel Palade bodies. Pulmonary artery and pulmonary
microvascular endothelial cells secreted low levels of FVIII and vWF to conditioned media, and demonstrated cell surface
expression of FVIII and vWF Ab–reacting proteins compared to an isotype control. Four endothelial splice isoforms were
identified. Two utilize transcription start sites in alternate 59 exons within the int22h-1 repeat responsible for intron 22
inversions in 40% of severe haemophiliacs. A reciprocal relationship between the presence of short isoforms and full-length
FVIII transcript suggested potential splice-switching mechanisms.
Conclusions/Significance: The pulmonary endothelium is confirmed as a site of FVIII secretion, with evidence of synthesis,
cell surface expression, and coexpression with vWF. There is complex alternate transcription initiation from the FVIII gene.
These findings provide a framework for future research on the regulation and perturbation of FVIII synthesis, and of
potential relevance to haemophilia, thromboses, and pulmonary hypertensive states.
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Introduction
Coagulation cascade activation is essential for normal haemo-
stasis [1]. Activated factor VIII (FVIIIa) is responsible for sustained
intravascular generation of thrombin via its role as a cofactor for
FIXa in the intrinsic Xase, with FVIIIa/FIXa ultimately respon-
sible for most of the FXa produced by both extrinsic (tissue-factor
initiated) and intrinsic coagulation cascades [2]. FVIII deficiency
leads to the bleeding disorder haemophilia A (OMIM +306700) [3].
Conversely, elevated levels of FVIII are emerging as one of the
strongest predictors of recurrent venous thromboembolic events
[4,5]. Venous thromboemboli (deep venous thromboses and
pulmonary emboli) carry significant health burdens [6], including
the development of chronic thromboembolic pulmonary hyper-
tension [7] in up to 3.8% of cases of pulmonary emboli at 2 year
follow up [8]. Elevated plasma levels of FVIII are unusual amongst
general thrombotic risk factors, as they are not only a risk factor
for venous thromboembolism, but also associated with chronic
thromboembolic pulmonary hypertension [9,10]. High levels of
von Willebrand Factor (vWF), the glycoprotein with which FVIII
circulates in a non-covalent complex [11], are also observed in
pulmonary hypertensive states [9,10].
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The liver produces sufficient FVIII for normal plasma levels
[12], with immunohistochemical evidence for stronger expression
by hepatic sinusoidal endothelial cells than hepatocytes [13].
Extrahepatic sources can also contribute to circulating levels of
FVIII, as demonstrated by the surprisingly high residual FVIII
plasma levels in dogs transplanted with haemophiliac livers [14].
We hypothesised that pulmonary endothelial cells might be a
source of plasma FVIII after demonstrating an age-independent
association between elevated plasma FVIII levels and pulmonary
arteriovenous malformations (AVMs) in hereditary haemorrhagic
telangiectasia (HHT) [15]. A pulmonary endothelial source of
FVIII would be of particular importance to these patients whose
ischaemic strokes are attributed to paradoxical thromboemboli
through pulmonary AVMs [16], and who are also at risk of several
pulmonary forms of pulmonary hypertension [17]. Pulmonary
endothelial synthesis of FVIII would also be of importance to
patients with in situ pulmonary thromboses, and potentially, of
immense importance to the haemostatic balance, since pulmonary
endothelial cells provide an endothelial-blood interface approxi-
mately twenty times all other vessels combined [18].
Others have demonstrated accumulation of FVIII in the effluent
from an isolated reperfusion model of lungs from three of four
heart-beating donors, and conditioned medium of early passage
pulmonary microvascular endothelial cells [19]. In this study, we
examined expression and processing of FVIII by a number of
normal pulmonary and systemic endothelial types, in situ and in
vitro, and compared to expression of von Willebrand Factor.
Materials and Methods
Subjects/Source of Endothelial Cells
a) Normal primary endothelial cells: Human pulmonary artery
endothelial cells (HPAEC), pulmonary microvascular EC
(HPMEC) and human dermal microvascular EC (HDMEC) were
purchased from PromoCell GmbH, Heidelberg, Germany. All
Figures are from lot numbers HPAEC 5060806.7, 5110901.3 and
6031391.3; HPMEC 7042502.7. Three lots of locally derived
human umbilical vein EC (HUVEC), derived from anonymised
and untraceable human umbilical cords, as specifically approved
by the Hammersmith Hospitals Research Ethics Committee (ref
no. 06/Q0406/21), were also studied. All EC were from separate
donors.
b) Human lung tissue: Frozen normal human lung tissue was
obtained from the Human Biomaterials Resource Centre of the
Hammersmith Hospitals Trust, with ethical approval from the
MREC for Wales (07/MRE09/54). In this protocol, written
consent for the use of waste material for research was part of the
procedural consent for the operation. This is obtained prior to the
procedure, and filed in the patient’s healthcare records. All tissue
handling was compliant with the requirements of the Human
Tissue Act (2004). Coded material was supplied accompanied by a
minimum data set (tissue type, pathology and clinical diagnosis
together with the age (in years) and ethnic group of the donor).
Five separate donors were examined.
Primary Antibodies
FVIII expression was primarily examined using a series of
hybridoma-derived murine anti-human FVIII:Ag IgG1 k mono-
clonal antibodies (C2, C5, C6 and C8 mAbs; Figure 1) which
display no vWF cross reactivity [23] and were used to purify FVIII
for the original Genentech cloning. FVIII ELISA experiments (see
below) utilised monoclonal antibody ESH-4 coated to the microtitre
wells as the capture antibody of the Imunobind FVIII ELISA (Axis
Shield, Bicton, UK, #ADI-884CON). Other primary antibodies
were obtained from DAKO UK Ltd, Ely, UK (monoclonal mouse
IgG1 antibody to Aspergillus niger glucose oxidase (X0931) as an
isotype control; anti-human CD31 clone JC70A (M0823); and
rabbit anti-human VWF polyclonal Ab (A0082)).
Immunohistochemistry
Serial sections from blocks from the five separate donors were
immunostained for 1 hour at room temperature with control
mouse IgG1 (20 mg/ml), anti-CD31 mAb (20 mg/ml), or FVIII C5
mAb (20 mg/ml). Stained sections were incubated with biotiny-
lated goat anti-mouse IgG (DAKO UK Ltd, Ely, UK) followed by
a Streptavidin alkaline phosphatase-conjugate (Roche Diagnostics
GmbH, Mannheim, Germany). Fast Red Kit (BioGenex, San
Ramon CA, USA) development was followed by Mayer
haematoxylin counterstaining.
Figure 1. FVIII genomic and domain structure. FVIII undergoes a complex series of steps between primary transcript synthesis and eventual
activity [20]. The 9 kb ‘full length’ 26 exon primary mRNA transcript is translated to a 360 kDa polypeptide chain which is translocated to the ER and
Golgi for post-translational processing including B domain proteolysis to generate the mature heavy and light chains [21,22]. Bars indicate the
epitope sites for mAbs C2, C5, C6 and C8 which react with the 360 kDa precursor, and the heavy (C2, C6, C8) or light chains (C5) [23]. Dotted lines
indicate the sites of previously described transcriptional silencing regions (see text).
doi:10.1371/journal.pone.0009154.g001
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Endothelial Cell Cultures
Human pulmonary artery endothelial cells (HPAEC), pulmo-
nary microvascular EC (HPMEC) and human dermal microvas-
cular EC (HDMEC) were from PromoCell GmbH, Heidelberg,
Germany. These primary human endothelial cells (not cell lines)
were ordered to arrive at passage two in a proliferating state: On
arrival, after inspection for confluency and viability, they were
rested for 2 hr at 37uC, 5% CO2, before the addition of fresh
reconstituted Promocell EC or microvascular EC (MEC) media
(2% and 5% fetal calf serum respectively), and subsequent passage
according to degree of confluency and experimental design.
Experiments were performed within 10–15 doubling times as
recommended. All Figures are from EC at passage 4–6.
Confocal Microscopy
EC were seeded at 36105 in individual wells of BD Falcon
CultureSlides (354118, BD Biosciences, Oxford, UK). After 24–
48 hr, media was either left in situ (unstimulated cells) or replaced
with fresh media containing 0.5 U/ml thrombin (T4393, Sigma
Aldrich, Gillingham, UK) for 6 hours. Following phosphate
buffered saline (PBS) washes, cells were fixed and permeabilised
with methanol at 220uC for at least 10 minutes. After methanol
aspiration, and two further PBS washes, cells were incubated with
100 ml of primary antibody (diluted to 1 ug/ml in 3% bovine serum
albumin (BSA) for the four mouse anti-FVIII mAbs; 3 mg/ml for
rabbit anti-vWF pAb), or control media for 15 minutes at room
temperature. Cells were washed in PBS, then incubated with 150 ml
of appropriate fluorescently conjugated secondary antibodies (Alexa
Fluor 488 goat anti-rabbit IgG or Alexa Fluor 555 goat anti-mouse
IgG) in 3% BSA, with or without Alexa Fluor 633 To-Pro-3 for
nuclear counterstain (all from Invitrogen, Paisley, UK). Following
incubation in the dark for 15 minutes, aspiration, and PBS washes,
the CultureSlide was disassembled, stained cells mounted in anti-
fade medium (VectashieldH, Vector Laboratories, Burlingame, CA,
USA), and imaged following no more than 3–4 days storage in the
dark at 4uC. Images were acquired using the Plan-Neofluor 20x/0.5
and 40x/1.30 objectives of an LSM 510 META inverted
fluorescence confocal microscope (Carl Zeiss, Welwyn Garden
City, UK). Each channel was collected sequentially using LSM
Image Browser software. In preliminary experiments in HPAEC, all
four FVIII mAbs demonstrated comparable staining patterns.
ELISAs
EC were seeded into 24 well plates and cultured to confluency.
500 ml of fresh media (+/20.5 U/ml thrombin (T4393, Sigma
Aldrich, Gillingham, UK)) was added, with at least three replicates
for each condition, donor or cell type. Conditioned medium was
aspirated from triplicate wells after 24 hr and 48 hr for immediate
storage in aliquots at 270uC. Reconstituted control media of each
type was also dispensed to 3 separate wells of a 6 well plate and
incubated at 37uC, 5% CO2 for 24 hours prior to immediate
storage in aliquots at 270uC. FVIII:Ag was detected using a
commercial FVIII ELISA (Immunobind ADI-884CON, Axis
Shield, Bicton, UK), with standard curves generated using supplied
lyophilised FVIII concentrates. VWF:Ag was detected as previously
described [24]. All samples were processed in duplicate. Optical
readouts were quantified on an Opsys MR Plate Reader using
Revelation Quicklink Software (both from Dynex Technologies,
Worthing, UK). All data sets were included in the final analyses.
FVIII Activity Assessments
Initial FVIII activity measurements were performed by running
diluted conditioned media through a CA7000 automated
coagulation analyser (Sysmex UK, Milton Keynes, UK) in the
hospital service laboratory. Samples were also analysed undiluted
in a manual one-stage assay in which 0.1 mls of congenital FVIII
deficient plasma (Technoclone Ltd, Dorking, UK), and 0.1 mls of
test plasma or media, were aliquoted into glass tubes, and a stop
watch started immediately after the addition to the tubes of
0.1 mls of APTT reagent (Actin FS, Dade, Sysmex UK Ltd,
Milton Keynes, UK). The time to the generation of a clot was
recorded.
Flow Cytometry
EC were seeded into 12 well plate wells and allowed to reach
confluency. Triplicate confluent samples of each HPAEC,
HPMEC and HUVEC were trypsinised, washed in Hanks
buffered saline solution (HBSS), and aliquoted into centrifuge
tubes for sedimentation, prior to resuspension in 50 ml residual
media, and addition of 50 ml HBSS and 1% fetal calf serum (FCS)
+/2 1 mg murine FVIII mAb C2, rabbit anti-vWF, or control
IgG1 for 20 minutes at 4uC. After washing and centrifugation, all
cells were resuspended in 50 ml residual media, and treated with
50 ml HBSS/1% FCS containing 1 mg of an appropriate
secondary conjugated antibody (Alexa Fluor 488 goat anti-mouse
IgG for FVIII and controls; Alexa Fluor 488 goat anti-rabbit IgG
for vWF). Cells were incubated in the dark for 20 minutes at 4uC,
prior to a further wash, PBS resuspension, and immediate analysis
using an EPICS XL flow cytometer (Beckman Coulter, High
Wycombe, UK). Relative fluorescent intensity (RFI) was calculat-
ed by dividing the mean fluorescent intensity of test antibody by
the fluorescent intensity of untreated or isotype control treated
cells from the same well. Hence no expression has an RFI of 1.00.
FVIII Transcript Analyses
RNA was extracted from EC at various degrees of confluency
using TriH Reagent (Sigma). Following quantification by optical
densitometry, 1 mg of RNA was used for cDNA synthesis using
SuperscriptTM II (Invitrogen, Paisley, UK). Oligonucleotide
primers were designed to constitutive and alternative exons of
the known FVIII transcripts (RefSeq [25] variants 1; NM_000132
and 2; NM_019863), and to novel exons identified by the
ExonMine project [26] through extensive mining of BLAT
alignments [27,28,29] to human genome NCBI Build 36.1 of
mRNA and expressed sequence tag (EST) sequences deposited in
the GenBank [30]. Rt-PCR products were purified by gel excision
or treated with an ExoSAP mix comprising 1.2 u of ExoI and
1.06 u of SAP (Promega, Southampton, UK), sequenced on an
ABI 3730x1 DNA analyser, and results analysed using FinchTV
V1 4.0 software (Geospiza, Seattle, USA). Confirmation of FVIII
transcript identity was obtained by Blastn (http://blast.ncbi.nlm.
nih.gov/Blast.cgi). Evolutionary conservation of flanking sequenc-
es was performed via the UCSC Genome Browser [29].
Analyses
The main outcome measures were i) endothelial cell reactivity
to Abs assessed qualitatively and semi-quantitatively (see below); ii)
ELISA quantification of conditioned media reactivity; iii) flow
cytometric quantification of cell surface reactivity; and iv)
comparison of transcript detectability by single and nested rt-
PCR reactions.
For confocal microscopy, FVIII and vWF expression levels per
cell were defined semi-quantitatively by examination of at least five
separate high power fields. FVIII expression was graded as
undetectable, weak and strong cytoplasmic expression. vWF
expression was recorded as 0, 10 or .10 Weibel Palade bodies
(WPB) per cell, with high level expression defined as.10 WBP per
Endothelial FVIII
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cell. The percentage of cells expressing the different levels was
expressed as mean6standard deviation, calculated using Graph-
Pad Prism version 4, GraphPad Software, San Diego, USA.
For ELISA and flow cytometry, no assumptions were made
about data distribution, and non-parametric analyses were
performed: Multiple group comparisons were performed using
the Kruskal-Wallis test on all datasets, with p values from post test
analyses of the indicated selected groups using Dunn’s Multiple
Comparison test. Two group comparisons were performed using
the Mann Whitney test.
Results
FVIII Protein Expression in Lung Tissue
Factor VIII expression by the pulmonary endothelium was
assessed in situ, by comparing serial sections from the same donor
blocks stained with the IgG1 isotype control mAb, CD31 mAb, or
C5 mAb to FVIII. As demonstrated in Figure 2, there was no
reactivity to staining using the isotype control antibody (Figure 2ai,
Figure 2bi). In contrast, anti-CD31 demarcated the endothelium
of pulmonary capillaries in interalveolar septae (Figure 2aii,
Figure 2bii), and staining was observed in a similar but less
extensive distribution using C5 mAb to FVIII (Figure 2aiii,
Figure 2biii). Comparable staining patterns were observed in the
other three cases examined.
FVIII Protein Expression by Endothelial Cells In Vitro
Using confocal microscopy, all four mAbs to both heavy (C2,
C6, C8) and light (C5) chains demonstrated significant reactivity in
HPMEC and HPAEC (Figure 3), HDMEC, but not HUVEC
(data not shown). In pulmonary EC, FVIII expression increased
with the degree of confluency (Figure 3ci), and for the pulmonary
and dermal microvascular EC, with the formation of vessel-like
structures in vitro. There was no difference in expression patterns
following EC treatment with thrombin for 6 hours (data not
shown). There was also no difference between appearances for the
four antibodies for the same EC lot.
Since vWF is required for stable accumulation of FVIII in
cellular supernatants [11], intracellular expression of FVIII and
vWF were compared. Anti-vWF defined classical Weibel Palade
bodies in a proportion of HPMEC and HPAEC, as in the original
description in pulmonary endothelial cells [31]. Expression of
VWF also increased with the degree of confluency (Figure 3ci).
Overall, a higher proportion of EC expressed vWF than FVIII
(Figure 3cii). Usually, high vWF and high FVIII expresssion did
not overlap in HPMEC (Figure 3d) or HPAEC. Where
coexpression did occur, generally the intracellular sites were non
overlapping, but in some HPAEC, colocalisation of FVIII and
vWF within the same cells appeared to be centred on vWF-
containing Weibel Palade bodies (Figure 3e, Figure 3f, Figure 3g).
FVIII/vWF Cell Surface Expression
FVIII expression was next examined on the surface of EC using
flow cytometry. HPAEC and HPMEC, but not HUVEC
demonstrated significant surface expression of FVIII compared
to control untreated (Figure 4a) and isotype control-treated
(Figure 4bi) cells from the same well. When compared to the
isotype control-treated HPAEC, the overall increase in RFI was
shown to reflect stronger staining of a small proportion of EC
(Figure 4bii, Figure 4biii). Expression of vWF on the cell surface of
a proportion of HPAEC was also detected (Figure 4c).
FVIII/vWF Secretion
Conditioned media from HPAEC and HPMEC, but not
HUVEC detected higher (low mU) levels of FVIII than respective
control media (Figure 4d). Overall, approximately 5 mU/mL
FVIII accumulated over 48 hours in the conditioned media from a
pulmonary EC surface area of 3.8 cm2. There was no significant
difference in the quantity of FVIII secreted into conditioned
medium supernatants following 24 or 48 hour treatment of
HPAEC or HPMEC with thrombin (individual p values .0.11,
data not shown). In addition, conditioned media from HPMEC
also had significantly higher mean levels of vWF antigen after
48 hours incubation (1.40 [SD 0.20] U/ml) compared to 24 hours
(0.74 [SD 0.058] U/ml).
To test whether the FVIII antigen was functional, manual
FVIIIc assays were performed. Standard curves were generated
using replicate serial dilutions of lyophilised FVIII concentrate
representing a range of 0.1% (0.001 U/ml) to 100% (1.0 U/ml).
Clotting times ranged from 58 seconds (1.0 U/ml FVIII) to 120
seconds (0.001 U/ml VIII), with a good standard curve
(r2 = 0.993, Figure 4e). In contrast, clotting times exceeded 240
seconds in all conditioned media samples, and no clot formation
was observed, even at 30 minutes. Diluted test samples were also
assayed using the automated CA7000 FVIIIc assay, but again, no
clot was detected in any sample.
Figure 2. Lung expression of FVIII. Serial sections of frozen normal human lung tissue from two donor blocks (a and b) stained with i) control
IgG1, ii) anti-CD31, or iii) anti-FVIII (C5). The 200x images are representative of data from all five donors.
doi:10.1371/journal.pone.0009154.g002
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Multiple FVIII Transcripts in Pulmonary EC
To confirm that FVIII was synthesised in endothelial cells,
polyadenylated FVIII transcripts were analysed by reverse
transcription (rt) using an oligo-dT primer and amplification of
cDNA products by specific polymerase chain reactions (PCR).
In nested rt-PCR reactions, in addition to full length FVIII
transcript (variant 1), three further transcripts were detected, the
known RefSeq variant 2 and two new transcripts (Figure 5, see
also exon positions in Figure 1). Variant 2, and novel variant 3
utilised different first exons (22B and 22A) within intron 22,
splicing to constitutive exon 23. Novel variant 4 had a first exon
(U1) derived from genomic DNA 4.3 kb 59 to the first exon of the
full length transcript, variant 1. All four transcripts were also
detected in dermal microvascular EC, and for all EC, FVIII
transcripts were detected more readily in equivalent concentra-
tions of cDNA derived from confluent EC (data not shown). The
four alternate first exons contained AUG start codons in-frame
with the open reading frame in subsequent exons. Between
different cell types, there was a possible reciprocal relationship
between expression of exon U1 (and exon 22B)-containing
transcripts with full length isoform sequence (Figure 5b). Exon
22A sequences amplified preferentially from pulmonary EC
(Figure 5b).
Coding transcripts of importance are subject to strong selective
pressure, as demonstrated by the strong evolutionary conservation
of exon 22 sequences encoding part of the FVIII light chain
(Figure 6a). The most striking feature of the alternate exons U1,
22A and 22B was the degree of conservation of 59 flanking
sequences, compared to those for exon 1, that are part of the
characterised FVIII promoter region [32,33] (Figure 6b, Figure 6c,
Figure 6d). Exons 22A and 22B are sited within the int22h-1 repeat
which shares significant homology with the int22h-2 and int22h-3
sequences also on the X chromosome (Figure 6e, Figure 6f).
Nevertheless, BLASTn alignments confirmed that the novel exon
sequences were identified only once in human genomic DNA
sequences.
Discussion
In this study we report that endothelial cells, particularly
pulmonary endothelial cells, are a source of FVIII synthesis, with
evidence of cell surface expression, secretion, and co-expression
with vWF. The study also highlights the complex alternative
splicing patterns employed by the FVIII gene in endothelial cells.
Limitations of the study include the relatively limited number of
donors examined, particularly for a protein with plasma
concentrations that can differ three-fold and remain within
normal laboratory ranges (45–158 iu/dl at our institution).
Nevertheless, in view of the potential implications of the findings
for haematological and pulmonary vascular disorders, we believe it
is important to bring our results to the attention of the wider
biomedical communities at this stage.
The study demonstrates that endothelial cells from several
vascular beds in addition to those of the hepatic sinusoid [13], and
Figure 3. Immunofluorescence images of FVIII expression by EC. a: Sequential confocal fluorescence microscopy images in primary human
EC. a and b: Representative HPMEC and HPAEC control images using To-Pro-3 nuclear counterstain (first panel, monochrome), murine control IgG1
(second panel monochrome) and merged images (third panel: To-Pro-3 nuclear counterstain white, control IgG1 red) using maximum gain used for
imaging. c) Comparison of proportion of i) HPMEC and ii) HPAEC expressing vWF and FVIII protein (expression levels defined in methods). d, e, f,
g) Sequential confocal fluorescence microscopy images comparing vWF (monochrome in first panel); FVIII (monochrome in second panel, specific
mAb as denoted), and merged images (third panel; vWF green, anti-FVIII reacting protein red) in d): HPMEC, and e, f, g): HPAEC. FVIII mAb images
displayed here are representative of all FVIII mAbs examined, and all cell lots. Note yellow merged images suggesting degree of FVIII/vWF
colocalisation in e, f, g, with white colouring denoting the nuclei (TO-PRO3 nuclear counterstain). Scale bars indicate 5 mm.
doi:10.1371/journal.pone.0009154.g003
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pulmonary microvascular circulation [19], can synthesise and
secrete FVIII. PubMed searches suggest apparently similar
findings were reported for ‘FVIII antigen’ in human umbilical
vein EC [34,35], but it is important to note that this work referred
to an antigen that was present at normal levels in haemophiliac
plasma, but at reduced levels in plasma from patients with von
Willebrand’s disease [35], representing what we would now term
VWF:Ag, as described in [36]. In our hands, HUVEC were not a
good source of FVIII, and indeed were used as a negative control
for ELISA and FACS analyses.
Secreted FVIII would be unstable unless associated with vWF.
Weibel Palade bodies, now recognised as VWF storage bodies,
were first described in pulmonary endothelial cells [31]. This study
demonstrates not only that endogenous vWF and FVIII can be
secreted and expressed by the same endothelial cells, but also, that
in some pulmonary artery EC, endogenous FVIII colocalises with
vWF-containing Weibel Palade bodies (Figure 4e, Figure 4f,
Figure 4g). Further support for this localisation is obtained from
the studies by others that have demonstrated recombinant FVIII
may localise within Weibel Palade bodies [37,38]. The FVIII
released into conditioned media in our experiments did not exhibit
procoagulant activity. Since even completely FVIII-deficient
plasma has an APTT less than 240 s, and others [19] detected
FVIII:c activity in pulmonary microvascular EC conditioned
media, we assume that particular media conditions may contain
inhibitors or proteolytic inhibitors. In addition, it is possible that
not all FVIII:Ag produced by pulmonary endothelial cells is active,
suggesting it may be important to explore further which specific
factors activate any latent antigen in vivo, in different experimental
media.
While general endothelial expression of FVIII:Ag is clearly
important, it is the particular contribution of the pulmonary
endothelial bed which carries greater potential to influence general
coagulation pathways: The pulmonary endothelial cell–blood
interface area exceeds 60 m2 [18]: Were in vitro accumulation
rates to be replicated from pulmonary EC in vivo, this would
approximate to constitutive secretion of FVIII:Ag of 16106 mU/
hr; or 50 mU per cardiac cycle. Taken together, these observa-
Figure 4. Secreted and cell surface FVIII. a) Quantification of FVIII on the surface of EC. Relative fluorescence intensity (RFI) of confluent
HUVEC, HPAEC and HPMEC stained with FVIII mAb C2, compared to EC from the same well in which C2 was omitted. b) Quantification of HPAEC
surface FVIII: bi Comparison of EC RFI for HPAEC from the same well treated with IgG1 control, or C2 mAb; p values calculated by Mann Whitney.
bii-iii. Representative raw data plots of log expression (FL1 log) versus forward scatter as a marker of cell size for HPAEC from the same well treated
with bii) IgG1 control, biii) C2 mAb. c) Quantification of HPAEC surface vWF. ci) Comparison of EC RFI for HPAEC from the same well treated
with IgG1 control, or vWF pAb, p values calculated by Mann Whitney. cii-iii. Representative raw data plots of log expression (FL1 log) versus forward
scatter as a marker of cell size for HPAEC from the same well treated with cii) IgG1 control, ciii) vWF pAb. d) Quantification of FVIII:Ag in control
and EC-conditioned media by ELISA. M1 denotes control EC media (2% FCS), M2 denotes control MEC media (5% FCS). M1 control data are
presented twice for clarity. P values are presented for the 48 hour data sets of EC from passages 4 and 5. Differences at 24 hours did not reach
statistical significance. e)Manual FVIII:c assay standard curve. Ln FVIII, logarithm of FVIIIc activity (U/ml). Note clotting time in samples exceeded
240 seconds.
doi:10.1371/journal.pone.0009154.g004
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tions suggest that the pulmonary endothelium could be one source
of the releasable pool of FVIII that can be secreted with vWF, as
predicted from clinical studies [39].
The potential for dysregulated release of FVIII by the
pulmonary endothelium may carry implications for two forms of
pulmonary hypertension. In chronic thromboembolic pulmonary
hypertension, 50% of patients have no evidence of a preceding
venous thrombus, leading to the concept that a primary
pulmonary arteriopathy and in situ thromboses could be causal
or contributory factors [40,41]. In primary pulmonary artery
hypertension, microvascular intrapulmonary thromboses are
recognised as part of the pathological spectrum. Both of these
pulmonary hypertension phenotypes are associated with elevated
total plasma levels of FVIII and vWF. The current findings that a
proportion of pulmonary EC express FVIII and vWF on the cell
surface, together with recent evidence that resting EC can
constitutively express membrane constituents involved in sustained
FVIII/IXa-dependent activation of FX [42], lead us to hypothe-
sise that dysregulated pulmonary endothelial FVIII processing
may contribute to exuberant local intravascular thrombus
formation in these pulmonary hypertension phenotypes. Further
work on tissues from patients with these pathologies is required to
support or refute this hypothesis.
A consistent feature of all experiments in this study was that
adjacent EC could express different levels of FVIII. We
hypothesised that this variation, and potentially the low level
steady state FVIII full length transcript mRNA levels and other
recombinant FVIII expression limitations observed by others
[11,21,43], may be due to expression of different splice isoforms of
FVIII by different cells. The current study provides evidence for
four alternate transcripts of FVIII in the endothelium. Noting that
alternate splicing and alternate transcription initiation are
recognised to provide major regulatory potential for higher
organisms [44], we considered whether the alternate FVIII splice
isoforms were likely to be important.
All three short transcripts have the potential to encode short
segments of FVIII protein sequence. While direct contribution of
any short transcript-encoded protein to FVIII catalytic activity
would be unlikely in view of the exons involved (Figure 1, Figure 6),
roles for such proteins facilitating or interfering with the complex
intermolecular associations required to generate activated FVIII
could be postulated. Alternatively, the option for alternative
transcript initiation may provide a further layer of regulatory
control: The short transcripts do not contain the sequences
previously implicated in FVIII transcriptional silencing [45], but it
is recognised that minigene insertion into FVIII intron 1 improves
Figure 5. FVIII splice isoforms. a: Variants identified by ExonMine: Variants 1 and 2 correspond to major and minor RefSeq isoforms; variants
3–5 to expressed sequence tag (EST) sequences deposited in Genbank. Note none of the alternate variants encode the FVIII mAb epitopes. b:
Variants identified in EC. Simultaneous expression of variants 1–4 in HPAEC (PA), HPMEC (PM), and HUVEC (H). Gels: wx, HaeIII-digested wx marker,
CA negative water control for HPAEC/HUVEC, CM negative water control for HPMEC. The apparent difference in size of variant 4 is an artefact due to
gel running (note differential site of 194 marker band in first and last lanes). Cartoons: Thin and thick arrows indicate sites of PCR and sequencing
oligonucleotide primers respectively. Sequence chromatograms were obtained using nested reverse internal primers in exon 23 (variants 1–3) or
exon 3 (variant 4; low concentration first round product sequenced). Note V5 sequences (exons U1-1-2-3) were not amplified from EC in any reaction.
doi:10.1371/journal.pone.0009154.g005
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in vivo production of FVIII [46]. Our data suggest that further
examination of whether trans expression of 22A-containing
transcripts facilitates FVIII processing, or whether switching to
U1- and 22B-containing transcripts limits full length FVIII
transcript production, may be informative.
Genome-wide analyses indicate that alternatively spliced
sequences expressed differentially between tissues are subject to
strong selective pressure [47], and there is clearly strong
conservation of sequences flanking the alternatively spliced first
exons U1, 22A and 22B. This suggests that these 59 flanking
sequences, sited up to 140kb from the characterised FVIII
promoter, may have functional roles, and that further evaluation
of promoter activity within these regions would be appropriate.
Other factors however, may be driving the evolutionary
conservation in these regions: First, there are genes on the
opposite strands of exon U1 (FUNDC2) and exons 22A and 22B
(H2AFB3). Second, exons 22A and 22B lie within the 9.5kb int22h-
1 sequence which undergoes intra-chromosomal gene conversion
with the repeats int22h-2 and int22h-3 [48]. This region is well
known to haematologists, since homologous recombination
between int 22h-1 and one of the telomeric repeats on the X
chromosome leads to the intron 22 inversion responsible for 40%
of severe haemophilia.
In summary, this study provides further evidence for endothelial
cell sources of FVIII expression of potential importance to
haematological disease states and pulmonary vascular thrombor-
egulation. Detailed evaluation of pathways governing FVIII:Ag/
FVIII:c relationships, and co-transcriptional modulation of
alternate FVIII splicing and transcription initiation by cell type
or exogenous stimuli may be required for a better understanding
of the molecular mechanisms regulating cell surface and plasma
levels of FVIII.
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